Nautilus Biotechnology Stock Investor Sentiment

NAUT Stock  USD 2.01  0.03  1.47%   
Slightly above 62% of Nautilus Biotechnology's investor base is looking to short. The analysis of the overall investor sentiment regarding Nautilus Biotechnology suggests that many traders are alarmed. Nautilus Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Nautilus Biotechnology's earnings reports, geopolitical events, and overall market trends.
  
over a month ago at finance.yahoo.com         
With 32 percent ownership, Nautilus Biotechnology, Inc. insiders have a lot riding on the companys f...
Yahoo News
over a month ago at thefly.com         
Nautilus Biotechnology just downgraded at Goldman Sachs, heres why NAUT
news
over a month ago at investing.com         
Goldman Sachs cuts Nautilus Biotechnology stock to sell
Investing News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.0 subject to Rule 16b-3
Macroaxis News
over a month ago at www.macroaxis.com         
Acquisition by Subra Sankar of 140000 shares of Nautilus Biotechnology at 3.78 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
Macroaxis News
over two months ago at www.macroaxis.com         
Acquisition by Gwen Weld of 160000 shares of Nautilus Biotechnology at 2.72 subject to Rule 16b-3
Macroaxis News
over two months ago at finance.yahoo.com         
3 US Penny Stocks With Market Caps Up To 400M
Yahoo News
over two months ago at globenewswire.com         
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with the Academy...
Macroaxis News: globenewswire.com
over two months ago at insidermonkey.com         
Nautilus Biotechnology, Inc. Q3 2024 Earnings Call Transcript
insidermonkey News
over two months ago at gurufocus.com         
Nautilus Biotechnology Inc Q3 2024 Earnings Call Highlights Strategic Advances and ...
Gurufocus Stories at Macroaxis
over two months ago at seekingalpha.com         
Nautilus Biotechnology GAAP EPS of -0.13 beats by 0.04
seekingalpha News
over two months ago at www.macroaxis.com         
Acquisition by Sujal Patel of 9267 shares of Nautilus Biotechnology at 2.7014 subject to Rule 16b-3
Macroaxis News
over three months ago at thelincolnianonline.com         
Nautilus Marine Services Trading Up 5.9 percent Whats Next?
news
over three months ago at news.google.com         
We Think Nautilus Biotechnology Can Afford To Drive Business Growth - Yahoo Finance
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Nautilus Biotechnology that are available to investors today. That information is available publicly through Nautilus media outlets and privately through word of mouth or via Nautilus internal channels. However, regardless of the origin, that massive amount of Nautilus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Nautilus Biotechnology news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Nautilus Biotechnology relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Nautilus Biotechnology's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Nautilus Biotechnology alpha.

Nautilus Biotechnology Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Additional Tools for Nautilus Stock Analysis

When running Nautilus Biotechnology's price analysis, check to measure Nautilus Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nautilus Biotechnology is operating at the current time. Most of Nautilus Biotechnology's value examination focuses on studying past and present price action to predict the probability of Nautilus Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nautilus Biotechnology's price. Additionally, you may evaluate how the addition of Nautilus Biotechnology to your portfolios can decrease your overall portfolio volatility.